vTv Therapeutics reports Q2 2026 results, reaffirms cadisegliatin trial timelines
The company said Phase 3 CATT1 enrollment should finish in the third quarter of 2026, with a related Phase 2a hybrid closed-loop study to begin before year end.
vTv Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, and gave a corporate update on August 6, 2026. The company said it expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026.1 CATT1 is testing cadisegliatin, described as an oral adjunctive therapy to insulin in individuals with type 1 diabetes.1
Beyond the Phase 3 trial, vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026, a randomized, double-blind, crossover, multicenter study evaluating cadisegliatin in T1D participants using hybrid closed-loop insulin delivery systems, intended to inform design and operational aspects of future Phase 3 research in this population.1
The company also plans a Key Opinion Leader event. In the fourth quarter of 2026, the company plans to host a KOL event focused on T1D, the unmet medical need of hypoglycemia, and the cadisegliatin Phase 3 clinical program.1
On finances, cash and cash equivalents as of June 30, 2026, were $86.6 million, compared to $88.9 million as of December 31, 2025.1 The company said based on its current cash position at the end of the second quarter of 2026, it expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout.1
R&D spending rose year over year. Research and development expenses were $8.8 million for the three months ended June 30, 2026, versus $4.1 million a year earlier, an increase the company attributed primarily to continued investment in the Phase 3 CATT1 trial.1 Net loss attributable to vTv shareholders was $13.1 million, or $1.05 per basic and diluted share, for the quarter, compared with a net loss of $6.0 million, or $0.92 per share, in the same period a year earlier.1
Cadisegliatin, also known as TTP399, has been granted Breakthrough Therapy designation by the FDA.1 The company noted the drug is under investigation and its safety and efficacy have not been established, with no guarantee of health authority approval or commercial availability.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.